Tests to customize treatment at the early stage
About 35% of cases of colon cancer are diagnosed at an early stage (stage 2). At this stage, the prospects of curing the disease are high, by surgically excising the tumor followed by adjuvant chemotherapy, the objective being to prevent recurrence of the colon cancer.
One of the key steps in planning treatment is understanding the likelihood of the recurrence of colon cancer and this risk is a key consideration when deciding whether or not a stage II colon cancer patient should receive chemotherapy after surgery.
For a patient who has stage III colon cancer, the risk of recurrence is a critical consideration when selecting the most suitable chemotherapy.
The Oncotype DX® Colon Cancer Assay provides a method for estimating the risk of colon cancer recurrence and allows you to make a more informed decision about adjuvant therapy.